Relationship between plasma sRAGE and heart function in patients with heart failure

doi:10.3969/j.issn.1006-7795.2014.06.023

Abstract

Abstract:

Objective To investigate the level of soluble receptor for advanced glycation endproducts(sRAGE) in patients with heart failure, to analyze the relationship between sRAGE and heart function. Methods Select 100 patients with heart failure treated in our hospital(NYHA Ⅱ-Ⅳ), at the same time collect 50 cases hospitalized without heart failure, record general condition, and use the ELISA method to detect the levels of plasma sRAGE, applied SPSS 16.0 software to carry on statistical analysis. Results The plasma sRAGE level was increased in patients with heart failure than the control group, showing a significant difference(P<0.01). Plasma sRAGE level in the control group was(0.562±0.473)ng/mL, in the heart failure group was(0.844±0.705)ng/mL. With the cardiac function classification increased, plasma sRAGE level was elevated also, the control group was(0.562±0.473)ng/mL, NYHAⅡ level group was(0.680±0.506)ng/mL, NYHAⅢ level group was(0.844±0.646)ng/mL, NYHAⅣ level was(1.077±0.910)ng/mL. there is a significant difference(P=0.004). The plasma level of sRAGE had negative correlation with LVEF in patients with heart failure. Conclusion The plasma level of sRAGE was elevated in patients with heart failure, the level of plasma sRAGE and severity degree of heart failure present a associated relationship, with NYHA heart function classification increased, the plasma sRAGE level was elevated too.

Key words: heart failure, soluble receptor for advanced glycation endproducts, severity level

CLC Number:

Guo Xinying, Guo Caixia, Du Fenghe, Chen Buxing. Relationship between plasma sRAGE and heart function in patients with heart failure[J]. Journal of Capital Medical University, 2014, 35(6): 805-808.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2014.06.023

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2014/V35/I6/805

References

[1] Bierhaus A, Humpert P M, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products[J]. J Mol Med, 2005,83(11):876-886.
[2] Sakurai S, Yamamoto Y, Tamei H, et al. Development of ELISA for sRAGE and its application to type 1 diabetic patients[J]. Diabetes Res Clin Pract, 2006,73(2):158-165.
[3] Raucci A, Cugusi S, Antonelli A, et al. A soluble form of the receptor for advanced glycation end products(RAGE) is produced by proteolytic cleavage of the membrane bound form by the sheddase a disintegrin and metalloprotease 10(ADAM10)[J]. FASEB J, 2008,22(10):3716-3727.
[4] Basta G, Sironi A M, Lazzerini G, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein[J]. J Clin Endocrinol Metab, 2006,91(11):4628-4634.
[5] 邵亚辉,许顶立.糖基化终极产物对心血管系统的损伤作用及干预措施[J].中国分子心脏病学杂志,2004,4(4):253-256.
[6] Petrova R, Yamamoto Y, Muraki K, et al. Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes[J]. J Mol Cell Cardiol, 2002,34(10):1425-1431.
[7] Raposeiras-Roubín S, Rodiño-Janeiro B K, Grigorian-Shamagian L, et al. Relation of soluble receptor for advanced glycation end products to predict mortality in patients with chronic heart failure independently of Seattle Heart Failure Score[J]. Am J Cardiol, 2011,107(6):938-944.
[8] Polyakova V, Hein s, Kostin S, et al. Matrixmetalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression[J]. J Am Coil Cardiol, 2004,44(8):1609-1618.
[9] Mahajan N, Dhawan V. Receptor for advanced glycation end products(RAGE) in vascular and inflammatory diseases[J]. Int J Cardiol, 2013,168(3):1788-1794.
[10] Devangelio E, Santilli F, Formoso G, et al. Soluble RAGE in type 2 diabetes: association with oxidative stress[J]. Free Radic Biol Med, 2007,43(4):511-518.
[11] Aleshin A, Ananthakrishnan R, Li Q, et al. RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model[J]. Am J Physiol Heart Circ Physiol, 2008,294(4):H1823-H1832.
[12] Norata G D, Garlaschelli K, Grigore L, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population[J]. Nutr Metab Cardiovasc Dis, 2009,19(2):129-134.
[13] Nakamura K, Yamagishi S, Adachi H, et al. Serum levels of soluble form of receptor for advanced glycation end products(sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes[J]. Microvasc Res, 2008,76(1):52-56.
[14] Katakami N, Matsuhisa M, Kaneto H, et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes[J]. Atherosclerosis, 2009,204(1):288-292.
[15] 陈建康,朱鹏立,杨津,等.吡哆胺和替米沙坦对血管紧张素Ⅱ诱导的大鼠心肌细胞氧化应激的影响[J].中国医科大学学报,2012,41(7):622-625.
[16] 张敏,郭彩霞,曾翔俊,等.sRAGE对缺氧/复氧心肌细胞氧化应激的影响[J].首都医科大学学报,2012,33(4):73-78.
[17] 董洪武,郭彩霞,等.缺血/再灌注损伤对大鼠心肌内源性可溶性糖基化终末产物受体分泌的影响[J].首都医科大学学报,2011,32(5):640-644.